Accelerate to discover

Back to filter

Related topics

Demonstrate the value of RareCyte Orion system via web-based Minerva viewer

RareCyte

Nov 25, 2022

The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...

All inside your incubator: xCELLigence eSight

Agilent technologies

Nov 3, 2022

Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight

RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis

RareCyte

Oct 19, 2022

Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...

AMI HTX installation in CEMEX Iasi, Romania

Spectral Instruments Imaging

Sep 30, 2022

Presentation movie

Dec 9, 2022

Outstanding post-sort sample recovery on the WOLF Cell Sorter

NanoCellect

Jun 14, 2022

The new WOLF G2 instrument has significantly expanded the capabilities of gentle benchtop microfluidic cell sorting...

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters

MOLECUBES

Jun 3, 2022

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine...

An experimental strategy for preparing circular ssDNA virus genomes for next-generation sequencing

Sage Science

Jun 1, 2022

Recent article from February 2022 shoes how size selection improved viral read mapping by over 90% for begomoviruses.

Dec 9, 2022

Extracellular Vesicle Purity Enhanced by Gen 2 qEV Columns With Customised Proprietary Resin

IZON

May 4, 2022

Izon Science has announced the launch of Gen 2, the enhanced range of qEV columns for size-exclusion...

Show all topics (10)

HistoQuest software in cancer research

Mar 22, 2016

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of Stat3 or IL-6 signalling in a Pten-deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19ARF as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF–Mdm2–p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify STAT3 and CDKN2A mutations in primary human PCa. STAT3 and CDKN2A deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14ARF expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition.

Read more

Scientific paper

Brand profile

TissueGnostics

TissueGnostics develops systems for automated identification and functional characterization of single cells in tissue sections, cultured and smeared cells as well as TMA. This includes automated image acquisition and image processing for immunohistochemistry and multi-chanel immunofluorescence.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey